Dendritic cell (tumor antigen-presenting, activated) (DC (no widely accepted unique abbreviation for this specific functional state; "DC" is standard for dendritic cell))

Dendritic cells are professional **antigen-presenting cells** critical for initiating adaptive immune responses. In the context of cancer immunity, **tumor antigen-presenting dendritic cells** capture antigens from dying tumor cells within the tumor microenvironment. Upon encountering these antigens—often through pattern recognition receptors like Toll-like receptors—they undergo maturation characterized by upregulation of MHC molecules and co-stimulatory signals. Matured/activated dendritic cells then migrate from the tumor site via chemokine gradients (e.g., CCR7) toward draining lymph nodes or tertiary lymphoid structures. In lymphoid tissues, they present processed **tumor-associated antigens** on MHC class I/II molecules to naïve T-cells—primarily activating cytotoxic CD8+ T-cells but also providing help signals via CD4+ helper T-cells—which is essential for effective anti-tumor immunity. The presence and activity level of stimulatory intratumoral dendritic cells correlate with better prognosis and improved response rates in patients receiving immunotherapy. However, within tumors these functions are often suppressed by factors present in the **immunosuppressive tumor microenvironment**, leading many intratumoral DCs into a dysfunctional state that impairs their ability to prime effective anti-tumor responses. Therapeutic strategies—including ex vivo-generated autologous DC vaccines loaded with patient-specific antigens—aim either at restoring endogenous function or supplementing it with functional equivalents. Note: The phrase "Tumor antigen-presenting dendritic cell activation" does not refer to a single molecular target but rather describes a cellular process/state involving multiple signaling pathways (e.g., NF-kB/MAPK/IRF), metabolic reprogramming events supporting activation/migration/glycolysis, and complex interactions between innate/adaptive arms of immunity. Therefore: is_incorrect: true — This entry refers not strictly to a discrete molecule/receptor but rather an important cellular process/state central for cancer immunotherapy development. If you require information about specific surface receptors involved in this process—such as Toll-like receptors on dendritic cells—or wish details about particular subtypes like conventional type 1/classical type I cDCs versus plasmacytoid pDCs involved specifically in anti-tumor responses, please clarify your request.

Other names

Tumor antigen-presenting dendritic cellActivated dendritic cellAntigen-presenting dendritic cell

Drugs and therapies targeting these cells act by: - Enhancing maturation/activation of DCs to improve tumor antigen presentation and T-cell priming - Promoting migration of activated DCs to lymph nodes where they stimulate T-cells - Overcoming tumor-induced dysfunction/immunosuppression in the tumor microenvironment